Welcome to your Daily Dose of Health Tech Innovation!
Stay ahead with the latest breakthroughs revolutionizing healthcare—from AI diagnostics to remote care solutions.
We bring you expert-curated insights, emerging trends, and must-know updates from the digital health frontier.
Whether you’re a clinician, innovator, or health tech enthusiast, this roundup delivers what matters most.
Let’s dive into the future of health, one innovation at a time.
MS Pharma Group Signs Exclusive Biosimilars Deal with Hetero
MS Pharma Group, a regional pharmaceutical leader operating across the Middle East and North Africa, has entered into an exclusive partnership with global drug manufacturer Hetero Group to localize five well established biosimilar medicines. The agreement focuses on key treatment areas such as oncology, immunology, and hematology and aims to expand access to advanced biologic therapies within Algeria and the wider region.
Interwell Health Appoints Dr. Carney Taylor as Chief Medical Officer
Interwell Health, a national leader in value-based kidney care and a division of Fresenius Medical Care, has appointed Carney Taylor, MD, MBA, as its new chief medical officer. Dr. Taylor will lead clinical strategy, physician engagement, and quality initiatives, succeeding Dr. George Hart, who retired as CMO on January 1 but will continue to support the organization in a strategic advisory capacity to ensure a smooth transition.
Study Confirms AISAP AI Can Detect Heart Disease from Ultrasound
AISAP, a leader in AI-powered point-of-care diagnostics, announced the publication of a new clinical study in the peer-reviewed journal Frontiers in Digital Health, providing strong evidence that its deep learning model can accurately identify major valvular disease and ventricular dysfunction using only a single focused ultrasound view. Remarkably, the AI achieves high accuracy even when images are captured by non-cardiologists with handheld devices.
Lunai Bioworks Expands AI Program for Alcohol Use Disorder Drugs
Lunai Bioworks, an AI-driven drug discovery and biodefense company has reached a significant milestone under its NIH STTR-supported initiative by generating high-resolution multidimensional behavioral profiles of ethanol exposure and alcohol withdrawal. Using high-throughput vertebrate screening, the company identified reproducible neurobehavioral patterns that are only partially addressed by existing therapies. These findings reveal previously underexplored biological pathways with strong potential for translation into new treatments. Building on this achievement, Lunai has launched a commercial drug discovery program focused on Alcohol Use Disorder, a condition affecting roughly thirty million people in the United States, most of whom receive no effective pharmacologic intervention.
EIB Funds SamanTree Medical with €20 Million for Real-Time Surgical Microscopy
SamanTree Medical, a European innovator in surgical imaging technology, has secured €20 million in funding from the European Investment Bank through its Venture Debt Instrument. The operation is supported by InvestEU, the European Union’s flagship program designed to mobilize over €372 billion in additional investment from 2021 to 2027. Olivier Delporte, CEO of SamanTree Medical, said that the rigorous evaluation process reflects the significance of the company’s technology, its development strategy, and its long-term vision to advance real-time, high-resolution imaging of excised tissue during surgeries.
Genentech Reports Positive Phase II Results for Obesity Drug CT-388
Genentech, part of the Roche Group, announced positive topline results from its Phase II CT388-103 trial evaluating CT-388, an investigational dual GLP-1/GIP receptor agonist for the treatment of obesity. The study found that once-weekly subcutaneous injections of CT-388, titrated up to 24 mg, led to significant placebo-adjusted weight loss of 22.5 percent at 48 weeks without reaching a plateau. A clear dose-response effect was observed across the study. For the treatment-regimen analysis, participants experienced an 18.3 percent placebo-adjusted weight loss with high statistical significance. At the highest dose, 95.7 percent of participants achieved at least 5 percent weight loss, 87 percent achieved 10 percent, 47.8 percent achieved 20 percent, and 26.1 percent achieved 30 percent or more. Additionally, 73 percent of participants who were pre-diabetic at baseline reached normal blood glucose levels by week 48 compared to just 7.5 percent in the placebo group.
ASCP and Pfizer Launch RFP for mCRC Biomarker Testing
The American Society for Clinical Pathology has announced a new Request for Proposals in partnership with Pfizer, with participation from the American Society of Clinical Oncology, to support Quality Improvement grant projects focused on biomarker testing in metastatic colorectal cancer. The initiative will provide funding of up to 250,000 dollars per project and is designed to strengthen how biomarker data is used to guide first line treatment decisions for patients with mCRC. The Request for Proposals is scheduled to open on January 26, 2026, and ASCP will oversee the administration and management of the program.
To share your insights, please write to us at sudipto@intentamplify.com
